MindMed begins Phase 3 trials of LSD-based treatment for anxiety
MindMed, a U.S.-based pharmaceutical company, has initiated Phase 3 clinical trials for its LSD-based drug, MM120 (lysergide d-tartrate), targeting generalized…
MindMed, a U.S.-based pharmaceutical company, has initiated Phase 3 clinical trials for its LSD-based drug, MM120 (lysergide d-tartrate), targeting generalized…
English 
French 
German 
Russian 
Spanish 
Belarusian 
Ukrainian